FDA
-
-
-
-
-
-
-
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
-
-
-
-
-
-
-
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR
-
-
-
-
-
-
-
Soleno Therapeutics reports early commercial traction for VYKAT XR
-
-
-
-
-
-
-
Soleno Therapeutics (SLNO) Highlights New Data on VYKAT(TM) XR
-
-
-
-
-
-
-
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia
-
-
-
-
-
-
-
Soleno Therapeutics Announces VYKAT(TM) XR Launch
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

